ROS1 and non-small cell lung carcinoma: Moreover, the third-generation inhibitor lorlatinib, which was developed as a more potent and CNS-penetrant ALK/ROS1 inhibitor, was also granted a breakthrough therapy designation for use in patients with ALK-positive metastatic NSCLC who have previously received one or more ALK inhibitors in April 2017 [9].